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Abstract 
The main active ingredient in cannabis, delta-9-tetrahydrocannabinol (THC), can acutely 
induce psychotic symptoms and impair episodic and working memory. Another major 
constituent, cannabidiol (CBD), may attenuate these effects.  This study aimed to 
determine the effects of THC and CBD, both alone and in combination on psychotic 
symptoms and memory function. A randomised, double-blind crossover design 
compared the effects of (i) placebo, (ii) THC 8 mg, (iii) CBD 16mg, and (iv) THC 8mg + 
CBD 16mg administered by inhalation through a vaporizer. Using an experimental 
medicine approach to predict treatment sensitivity, we selected 48 cannabis users from 
the community on the basis of 1) schizotypal personality questionnaire scores (low, 
high) and 2) frequency of cannabis use (light, heavy). The Brief Psychiatric Rating Scale 
(BPRS), Psychotomimetic States Inventory (PSI), immediate and delayed prose recall 
(episodic memory), 1- and 2-back (working memory) were assessed on each day. 
Results indicated that THC increased overall scores on the PSI, negative symptoms on 
BPRS, and robustly impaired episodic and working memory. Co-administration of CBD 
did not attenuate these effects. CBD alone reduced PSI scores in light users only. 
Conclusions: At a ratio of 2:1, CBD does not attenuate the acute psychotic and memory 
impairing effects of vaporized THC. Frequent cannabis users may show a blunted anti-
psychotic response to CBD, which is of concern due to the high rates of cannabis use 
disorders in patients with schizophrenia. 
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Introduction 
Cannabis (marijuana) is used by over 180 million people worldwide(1).  Possible 
consequences of use include dependency, cognitive impairment, and increased risk of 
psychotic illness(2). However, most people who try cannabis do not experience 
prolonged adverse effects. Several factors predict vulnerability, including the rs2494732 
locus of the AKT1 genotype(3-5), adolescent exposure(6, 7), frequency of use(8-10), 
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schizotypy or schizophrenia(11-15) and the type of cannabis used(2, 16). Although it is 
typically classified as a single drug, the cannabis plant can contains over 100 unique 
‘cannabinoids’, with diverse and sometimes opposing pharmacological actions(17). 
Cannabis containing high levels of delta-9-tetrahydrocannabinol (THC) and little if any 
cannabidiol (CBD) is becoming increasingly prevalent(18, 19) and is linked to greater 
cannabis dependency, memory impairment and paranoia(20) and increased risk of 
psychotic illness(21). 
 
Delta-9-tetrahydrocannabinol (THC) produces the effects that users seek from 
cannabis, including ‘stoned’, ‘like drug effect’ and ‘want more drug’(22, 23). THC elicits 
robust, dose-dependent impairments in immediate and delayed verbal memory(2, 24) 
and transient positive and negative symptoms reminiscent of schizophrenia(25, 26). 
Cannabidiol (CBD) is non-intoxicating and does not influence ratings of ‘stoned’ 
following the administration of THC or cannabis (2, 16). However, CBD can produce 
opposite effects to THC across a range tasks and functional neuroimaging 
assessments(26, 27, 28). In terms of behavioural effects, CBD given alone was found to 
improve memory consolidation(29) and in combination with THC is associated with 
higher recognition memory scores in chronic cannabis users(30). CBD also appeared to 
block the impairing effects of THC on verbal recall in a naturalistic study(31), which was 
replicated in a laboratory study of oral CBD and intravenous THC(32).  
 
In terms of psychosis, CBD displayed equivalent efficacy to a standard antipsychotic drug 
for the treatment of positive and negative symptoms(33). A preliminary study with 6 
volunteers found that oral CBD pre-treatment reduced acute psychotic symptoms 
following intravenous THC(26). In a subsequent study of 48 volunteers, CBD reduced 
the incidence of clinically significant positive psychotic symptoms (but not their overall 
severity) following intravenous THC(32). However, a naturalistic study did not find 
evidence for protective effects of CBD on THC-induced psychotic-like symptoms(31). 
Chronic exposure to CBD has also been linked to fewer psychotic-like symptoms in 
those who have been exposed to THC(34), a finding that was replicated in light but not 
heavy cannabis users(30). 
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Taken together, the available data provides some evidence that CBD protects against 
the harmful effects of THC on memory and psychotic-like symptoms. However, only 
one study has examined the interactive effects of inhaled THC and CBD (58) no study 
to our knowledge has examined the interactive effects of THC and CBD on these 
variables in an experimental design with an inhaled route of administration(35), which 
better reflects how cannabis is typically administered than oral or intravenous routes. 
Furthermore, preliminary data suggest that frequency of cannabis use and schizotypy 
may predict how an individual responds to THC and and/or CBD. However, we are 
unaware of any experimental studies comparing the effects of different cannabinoid 
combinations (e.g. THC, THC+CBD, CBD) among volunteers selected for their 
vulnerability or resilience. 
 
Here, we adopted an experimental medicine approach in order to assess the effects of 
cannabinoids on psychotic-like symptoms and memory function. A randomised, double-
blind, crossover design was used to mimic the effects of cannabis with varying 
cannabinoid concentrations, as well as CBD alone. Across four sessions, each volunteer 
received THC (8mg), THC (8mg) + CBD (16mg), CBD (16mg) and placebo (ethanol 
vehicle). We predicted, firstly, that memory impairment and psychotic-like symptoms 
would occur following THC, secondly, CBD would offset these effects when co-
administered with THC, and thirdly, CBD alone would have pro-cognitive and anti-
psychotic effects. In order to extend previous work showing that schizotypy/psychosis 
and cannabis use frequency are possible vulnerability/resilience factors cannabis users 
were selected from a large-scale study on the basis of their cannabis use and schizotypal 
personality scores(30). We predicted that infrequent users(8-10, 30) and people with 
high psychosis proneness(11, 12, 14, 15) would show heightened susceptibility to THC, 
CBD, and their interactive effects. 
 
Methods 
Participants 
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Participants were recruited on the basis of having previously volunteered in a large scale 
study of over 400 cannabis users(30). Those scoring in the top and bottom quartiles of 
1) Schizotypal Personality Questionnaire score (low, high) were invited to take part, 
from this group we set out to recruit  24 light (1-24 days per month) and 24 heavy (25+ 
days per month) cannabis users..  Additional data from this study on facial affect 
recognition and effects on a visual analogue scale have been reported elsewhere(36). 
 
Subjects were matched for age and estimated premorbid verbal intelligence (as 
measured by the Spot the Word task(37)) across heavy and light users. Inclusion criteria 
were: (i) self-reported abstinence from cannabis, other drugs and alcohol use for 24h 
prior to each test day; (ii) fluent in English, (iii) normal or corrected to normal vision. 
Exclusion criteria were: current self-reported (i) respiratory health problems or physical 
health problems, (ii) pregnancy or the risk of being pregnant, (iii) clinically diagnosed 
learning impairments, (iv) clinically diagnosed schizophrenia/psychosis or substance 
abuse problems, and (v) no illicit drug use other than cannabis more than once a week. 
 
Design  
A four session, randomised, double-blind crossover design was used to compare the 
acute effects of THC (8mg), CBD (16mg) and their combination (8mg THC+16mg CBD) 
with placebo (ethanol vehicle). Both cannabinoids were formulated in alcohol solution 
and were purchased from STI Pharmaceuticals (Brentwood, Essex, UK). A total of 48 
volunteers completed the study, comprised equally from the following groups: low 
schizotypy, light cannabis users (LS-L); low schizotypy, heavy users (LS-H); high 
schizotypy, light users (HS-L); high schizotypy, heavy users (HS-H). N=12 per 
experimental group was chosen to detect THC-induced (compared to placebo) 
impairment in memory at a power of 0.83(22). Treatment order across the 4 sessions 
was determined by a balanced Latin square. 
 
Procedure 
Experimental sessions occurred on four  occasions each separated by a one-week wash-
out to minimize carry-over effects (>3 times elimination half-life of THC(25)). We used 
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urine and saliva screens to verify drug use. Participants completed baseline assessments 
before, and then commencing 10 minutes after drug administration. The full test battery 
took approximately 1.5 hours on each test day. Participants were reimbursed £120 for 
their time on the last testing day and debriefed fully. All participants provided written, 
informed consent on each occasion and ethical approval was given by the UCL Research 
Ethics Committee.    
 
Drug administration 
Cannabinoids and placebo (ethanol vehicle) were administered using a Volcano Medic 
Vaporisor (Storz & Bickel, Tuttlingen, Germany). 8mg THC dissolved in ethanol and 
16mg of CBD dissolved in ethanol(36) were administered on a 10-second inhalation 
cycle wherein participants was instructed to first fully exhale, next fully inhale from the 
balloon, hold their breath for 10 seconds and then fully exhale; this was repeated until 
the balloon was empty(38). This inhaled dose of THC has been found to produce effects 
on human brain and behavior, including psychotic-like symptoms and memory 
impairment(7, 38, 39). The 2:1 ratio of CBD:THC reflects the upper limit (mean +3 SD) 
found in high CBD/low THC cannabis preparations(40). Participants were given a test 
balloon to familiarise themselves with the procedure before any drug administration 
occurred.  The balloon was filled, covered with an opaque bag, and administered by an 
independent researcher so that the experimenter collecting behavioural data and 
participant was blind to drug condition.  
 
Assessments 
Before drug administration participants completed the Beck Depression Inventory(41), 
Spielberger Trait Anxiety Inventory(42), Schizotypal Proneness Questionnaire(43) and 
Spot the Word Test(37). After drug administration, the 48-item Psychotomimetic States 
Inventory(44) was used to assess acute schizotypal symptoms. It has subscales of 
perceptual distortion, cognitive disorganisation, anhedonia, mania, paranoia and 
delusionary thinking. Each item is rated from 0 (not at all) to 3 (strongly) on statements 
describing current experiences.  Current psychiatric symptoms were assessed with the 
experimenter-rated Brief Psychiatric Rating Scale(45) rated from 0 (not present) to 7 
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(extremely severe) with subscales of positive symptoms and negative symptoms. 
Participants also completed cognitive measures post-drug administration. 
 
Cognitive measures 
Prose Recall 
Verbal memory was assessed using immediate and delayed prose recall(46). Participants 
were required to recall a short passage of prose (30 second news bulletin) immediately 
and after a 20 minute delay filled with other assessments. 4 versions of the prose recall 
were administered in a counterbalanced order.  
 
N-back 
This task taps spatial working memory with an increasing load. It has previously shown 
sensitivity to acute(47) and chronic(48) drug effects. The participant was presented with 
a symbol (smiley face) in one of six spatial locations.  A fixation cross remained in the 
centre of the screen throughout the task.  When the next face appeared, they were 
required to indicate whether it was in the same location as the previous face in the 1-
back version of the task, or the same location as the face two positions before (2-back). 
Each block consisted of 25 “match” and 25 “no-match” trials in random order, i.e. 50 
trials in total, preceded by ten practice trials.  All symbols were presented 5cm from the 
fixation cross.  Each symbol was presented for 300ms with an inter-stimulus interval 
(ISI) of 450 msec. Versions were randomised across testing days. 
 
Fluency (57) 
To assess phonological and sematic fluency respectively, participants were asked to 
generate as many words as possible in 60 seconds starting with a pre-determined letter, 
or exemplars related to a pre-determined category. On each testing day participants 
generated exemplars of one letter and one category.   
 
Reitan’s Trailmaking Test (TMT: 59) 
Processing speed was measured using the TMT (Form A and B).  Form A requires 
participants to connect 25 numbers in an ascending numerical sequence. Form B 
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requires participants to connect 13 numbers (1-13) and 12 letters (A-L) in an ascending 
number-letter sequence. The dependent variable is time to complete the task, and then 
the time to complete the B form subtracting the basic psychomotor speed (B-A). 
 
Statistical Analysis 
Data were analysed using IBM SPSS version 20.  
Demographics and scores on questionnaires were analysed using repeated measures 
ANOVAs with two between-subjects variables (frequency of use, schizotypy). 
Assumptions of parametric tests were examined and data were transformed where 
they were not normally distributed, however in practice this did not alter the 
outcome so the of the analyses of the untransformed data are reported.Drug was 
entered as a within subjects factor, and was coded as a simple contrast (Placebo versus 
THC, Placebo versus THC+CBD, Placebo versus CBD). Additional within subjects 
factors were added where appropriate (Subscale for the Psychotomimetic States 
Inventory and Brief Psychiatric Rating Scale, Delay for prose recall, Load for N-back). 
Interactions with Drug were explored using simple contrasts. Interactions between 
other factors in repeated measures ANOVA models were analysed using pairwise 
comparisons with a local Bonferroni correction. Pearson correlational analyses were 
performed to explore the impact of frequency of cannabis use on any drug effects, and 
were also Bonferroni-corrected. All statistical tests were two-tailed and p values are 
displayed uncorrected in the text. 
 
Results 
Group characteristics 
As shown in Table 1, groups did not differ in age (F(3,44)=2.540, p=0.069), gender 
(X2(3)=4.437, p=0.218), years of education (F(3,44)=1.575, p=0.209), scores on the spot the 
word task (F(3,44)=0.802, p=0.499), last use of cannabis (F(3,44)=1.223, p=0.313), or number 
of years cannabis had been used (F(3,44)=0.666, p=0.578). BDI scores were missing for 
two participants (heavy user, low schizotypy group) and were replaced with the group 
mean. There was a main effect of schizotypy on scores on the SPQ (F(1,44)=12.473, 
p=0.001), BDI (F(1,44)=14.989, p<0.001) and STAI (F(1,44)=9.054, p=0.004) where the high 
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schizotypy group had higher scores than the low schizotypy group for each measure. 
Light and heavy users of cannabis differed on the time to smoke a standard quantity of 
cannabis sold in the UK (3.5g; 1/8oz) (F(1,44)=8.539, p=0.005) and on the number of days 
per month they used cannabis (F(1,44)=32.295, p<0.001) where heavy users smoked 3.5g 
in fewer days, and used cannabis on more days per month than light users. There were 
no differences in the number of people who had used tobacco (X2(3)=4.457, p=0.208), 
days since last use of tobacco (F(3,33)=0.592, p=0.625), years of tobacco use (F(3,31)=0.352, 
p=0.788), or days per month of tobacco use (F(3,31)=0.688, p=0.566). For alcohol, no 
differences were found for years used (F(3,44)=0.207, p=0.891) or days per month of use 
(F(3,44)=0.693, p=0.561). 
 
Psychotomimetic States Inventory (PSI) 
There was a main effect of Drug (F(2,105)=5.550, p=0.003, ŋp2=0.112), driven by increased 
scores relative to placebo for THC (p=0.014) and THC+CBD (p=0.022) but no change 
following CBD (p=0.544). 
An interaction between Drug and Subscale was found (F(6,267)=4.881, p<0.001, ŋp2=0.100) 
reflecting increased scores following THC and THC+CBD compared to placebo for the 
subscales of ‘Perceptual Distortion’ (THC: p=0.006; THC+CBD: p=0.005; Figure 1B) 
and ‘Cognitive Disorganisation’ (THC: p=0.008; THC+CBD: p=0.004; Figure 1C). CBD 
did not elicit change relative to placebo for any of these individual subscales, and no 
drug effects were found for the remaining subscales of ‘Anhedonia’, ‘Delusory Thinking’, 
‘Mania’ and ‘Paranoia’ (Figure 1).   
 
There was also an interaction between Drug and Frequency of use (F(2,105)=3.582, 
p=0.024, ŋp2=0.075). Exploration of the interaction showed that light and heavy users 
had similar responses to THC (p=0.504) and THC+CBD (p=0.977) relative to placebo, 
but reacted differently to CBD (p=0.005). As shown in Figure 2, CBD reduced PSI 
scores relative to placebo in light users (p=0.015), but not in heavy users (p=0.104) as 
shown in Figure 2.  
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Additionally, there was a Schizotypy by Subscale interaction (F(3,150)=6.856, p<0.001, 
ŋp2=0.135), as shown in Table 2.  Across all drug sessions, high schizotypy volunteers 
experienced greater PSI scores for ‘Anhedonia’ (p<0.001), ‘Cognitive Disorganisation’ 
(p=0.001), ‘Mania’ (p=0.004), and ‘Paranoia’ (p=0.007) relative to those with low 
schizotypy, but no differences were found for ‘Delusory Thinking’ or ‘Perceptual 
Distortion’.  
 
Significant main effects were found for the factors of Subscale (F(3,150)=80.254, p<0.001, 
ŋp2=0.646) and Schizotypy (F(1,44)=15.271, p<0.001, ŋp2=0.258).  
 
Brief Psychiatric Rating Scale (BPRS) 
There was no main effect of Drug. An interaction between Drug and Subscale was found 
(F(3,132)=3.396, p=0.020, ŋp2=0.072) as well as a main effect of Subscale, reflecting higher 
scores for Positive relative to Negative items on the BPRS (F(1,44)=122.149, p<0.001, 
ŋp2=0.735). There were no other significant effects or interactions. Exploration of the 
Drug by Subscale interaction revealed that for Positive items, cannabinoid administration 
had no effects, but for Negative items both THC (p=0.025) and THC+CBD (p=0.008) 
increased scores relative to placebo (Figure 3). 
 
Prose Recall 
There was a main effect of Drug (F(3,132)=4.458, p=0.005, ŋp2=0.092) which was driven by 
impairments following THC (p=0.031) and THC+CBD (p=0.024) relative to placebo, 
whilst CBD had no effect (Figure 4). A main effect of Delay was also found, reflecting 
poorer recall at delayed compared to immediate recall (F(1,44)=47.794, p<0.001, 
ŋp2=0.521). 
 
Spatial N-back 
There was also a main effect of Drug (F(3,129)=3.421, p=0.019, ŋp2=0.074), due to a 
reduction in sensitivity following THC (p=0.012) and THC+CBD (p=0.020) compared to 
placebo, but no differences for CBD (p=0.532), Figure 5A.  Data for was excluded for 
one participant on the 1-back task due to an excessively high rate of incorrect 
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responses (69%; chance level: 50%), suggesting they had misunderstood the task 
instructions.  Analysis of d’ scores revealed a main effect of Load (F(1,43)=16.818, p<0.001, 
ŋp2=0.281), attributable to higher d’ (sensitivity) on the 1-back compared to the 2-back 
task (Figure 5A). Analysis of RTs on correct trials revealed a main effect of Load 
(F(1,43)=18.951, p<0.001, ŋp2=0.306), due to faster responses on the 1-back compared to 
the 2-back task (Figure 5B) but no effect of Drug. 
 
Fluency  
Analysis of exemplars produced on the semantic fluency task revealed a significant effect 
of Drug (F(3,132)=6.029, p=0.001, ŋp2=0.121) which was driven by higher scores following 
THC+CBD (M:19.00, SE: 0.546) compared to placebo (M:16.63, SE: 0.655) (p=0.005) 
but no differences for THC (M: 17.2 SE:0.68)  or CBD (M:14.3 SE:. 0.34)  No significant 
effects emerged for the number of exemplars produced, or errors, on phonological 
fluency. No effects were found for semantic fluency errors. 
 
 
Retain’s Trailmaking Test 
For part A, a significant effect of Drug was found (F(3,132)=4.211, p=0.013, ŋp2=0.087). This 
was driven by faster completion following CBD (M: 14.20, SE: 0.47) compared to 
placebo (M: 15.76, SE: .76) (p=0.045) but no differences for THC or THC+CBD. No 
significant effects were found for part B, or for part B-part A. 
  
Correlations 
Since the effects of CBD on the PSI were moderated by frequency of cannabis use, 
correlations were carried out between the effects of CBD on total PSI scores (CBD – 
placebo) and indices of cannabis use (days of cannabis use per month, years of cannabis 
used) separately in light (n=24) and heavy users (n=24). No correlations were found in 
light users. In heavy users, a trend for a positive correlation emerged for years of 
cannabis use (r=0.434, p=0.034) indicating that a longer history of cannabis use was 
associated with blunted antipsychotic effects of CBD.   
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Discussion 
The main findings of this study were an increase in psychotomimetic symptoms 
following administration of both THC alone and the combination of THC+CBD. 
Administration of both THC and the combination (THC+CBD) increased negative 
symptoms on the BPRS, along with perceptual distortions and cognitive disorganisation 
on the PSI. Lower frequency cannabis users experienced a reduction in psychotomimetic 
symptoms following CBD alone compared with placebo. Both THC and THC+CBD 
impaired performance on episodic and working memory tasks. Contrary to hypotheses, 
CBD did not offset the psychotomimetic effects of THC.  
 
In line with previous studies, we found that THC in the laboratory at a dose of 8 mg 
inhaled in a Volcano vaporiser increased some psychotic-like symptoms(7, 38). Contrary 
to predictions, CBD when given concurrently with THC in a 2:1 ratio had no impact on 
psychotomimetic symptoms, which were still higher than placebo or CBD alone. It has 
previously been suggested that CBD may ameliorate the harmful effects of THC on 
psychotic-like symptoms(49) which has been supported by some empirical evidence(27, 
30, 32) including two experimental studies (n=6 in a crossover(27) and n=48 in parallel 
groups(32)). The latter study(32) found a reduction in positive psychotic symptoms 
following intravenous THC, which did not reach significance following pre-treatment of 
oral CBD. However, a significant protective effects of CBD was found when the authors 
compared the number of people who met clinically significant psychosis (an increase 
from baseline of ≥3 points(15)). It may be the case therefore, that CBD is only 
protective when THC induces a strong psychotic reaction, which might be achieved by 
using higher doses of THC. In the current study, although THC increased scores on the 
PSI (perceptual distortion and cognitive disorganization) and BPRS negative symptoms, it 
did not increase BPRS positive or PSI paranoia scores at a group level. This in itself is 
interesting as the same dose and administration route used here has been reliably 
shown to increase these symptoms in other studies (e.g. 38), possible reasons maybe 
repeating each of these measures in this four-way crossover design. Additionally both 
our groups were heavier cannabis users than previous studies which have administered 
similar doses in the lab and tolerance to psychotomimetic effects has been previously 
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shown (D’Souza et al., 2005). Another important consideration is that it is unclear 
which CBD:THC ratio is most effective for reducing harm(16). In this study doses of 
8mg THC and 16 mg CBD were chosen to create a CBD:THC ratio of 2:1, reflecting 
the upper limit (mean +3 SD) found in high CBD/low THC cannabis preparations(40). In 
addition, Englund et al. pre-treated volunteers with oral CBD (600mg) and before 
intravenous THC (1.5mg/kg). These very different doses and routes of administration 
(which influence absorption and metabolite profiles(50)) may account for our divergent 
findings. In street cannabis, findings from our own lab did not suggest an acute protective 
effect of CBD against the psychotomimetic effects of THC(31) but rather a chronic 
effect, related to levels in hair(30, 49), which is in accordance with the findings of this 
current study.   
 
Similarly with cognition, impairments to working and episodic memory were observed 
following both administration THC and the combination of THC+CBD. Contrary to our 
predictions, CBD did not offset the effects of THC. This differs from our naturalistic 
findings where users smoking cannabis with higher levels of CBD resulted in less 
impairment than those with lower levels(31). One reason for this difference from 
naturalistic findings could be other chemicals present in whole plant cannabis material, 
including terpenes(51), which do not occur in our synthetically produced cannabinoids. 
However, interactive effects of CBD and THC on memory function were also reported 
by Englund et al. in a controlled study of synthetic oral CBD and intravenous THC(32). 
Moreover, in the current data we also found that CBD improved facial affect 
recognition when administered alone, and offset impairments on the same task when 
co-administered with THC(36). It is worth noting that the protective effects in CBD 
that study were of a small effect size, and limited to a single intensity of facial stimuli 
(40%)(36). Moreover, CBD was not protective of immediate verbal recall in Englund et 
al.(32), and although it showed evidence for a protective effect on delayed recall, these 
were not supported by a significant condition by group interaction. Thus, taken 
together, the ability of CBD to protect against THC-induced cognitive impairment may 
be of a small effect size, and/or influenced by vulnerability factors which have not been 
considered in research studies to date. 
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One interesting and unexpected finding was of the greater number of  correct 
exemplars generated following THC+CBD than placebo, but no differences between 
placebo and THC alone and CBD alone. This is partly in line with previous findings with 
cannabis users (Schafer et al., 2010) of increases in divergent thinking following acute 
cannabis use. This increase occurred only in the group given CBD alongside THC, one 
possible tentative explanation is that CBD’s pro-cognitive effects combine with the 
ability of THC to stimulate novel thinking to result in successful task performance.  
 
In this study, no tolerance to the cognitively impairing or psychotomimetic effects of 
THC was observed for high compared to low frequency users which contrasts with 
previous studies(8-10). Differences between these studies could be attributable to dose 
and/or route of administration (e.g. smoked or intravenous versus vaporized). 
Additionally, previous studies suggesting tolerance develops to the acute cognitive 
impairing effects of THC have generally been small-scale. However, our findings are 
consistent with a recent study which like ours, used inhalation of THC via a volcano 
vaporiser(52). This was a large-scale, cross-over study with 122 participants ranging 
from daily cannabis users to very infrequent users (as low as once in the last 3 months).  
Like our present data, they found no evidence of tolerance to the impairing effects of 
acute THC on neurocognitive function.    
 
Our rationale for including users high and low in schizotypy was that those high in 
schizotypy may be more vulnerable to the pro-psychotic effects of THC(11-14). 
however this hypothesis was not borne out in the data. Additionally we saw no evidence 
of tolerance to the psychotomimetic effects when THC was administered in this manner 
in the lab to heavy cannabis users, when compared to lower frequency users, in contrast 
to previous findings(8). There may be a variety of reasons for this, including the fact that 
the current study used a relatively low dose of THC (8mg) compared to doses 
estimated in naturalistic studies (~35mg in the UK(40); ~32mg in the Netherlands(53)). 
The inhalation procedure was standardised, with the aim of  controling for dose 
titration that may occur with cannabis smokers in a naturalistic setting(40, 53). Previous 
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studies investigating associations between schizotypy and acute psychotomimetic effects 
of cananbis/THC have used naturalistic designs(11, 12) or retrosepctive reports of drug 
effects(13, 14). It is therefore possible that differences in dose, smoking behaviour and 
expectancy/recall may have influenced these findings to some extent. A controlled 
study(15) reported similar psychotomimetic effects of THC in people diagnosed with 
schizophrenia and controls. 
 
An interesting finding to emerge from this research was that CBD alone reduced 
baseline levels of psychotomimetic symptoms in light but not heavy users. Moreover, we 
found a trend level correlation in heavy users, suggesting that the antipsychotic effects of 
CBD were increasingly blunted as years of cannabis use increased. This finding is broadly 
consistent with our previous finding that CBD in hair was associated with fewer 
psychotic-like symptoms in light but not heavy users(30).  This relates to recent work 
suggesting that CBD may be a potential treatment in schizophrenia through boosting 
brain levels of anandamide(33). Crucially, that study excluded patients with a positive 
urine screen for cannanabinoids, which might have influened their antipsychotic 
response to CBD. The effect of CBD observed in this study was confined only to low 
frequency users, suggesting a potential tolerance to these effects in higher frequency 
users, which may have implications for the future use of this compound in the treatment 
of schizophrenia, which is highly co-morbid with cannabis use disorders(54). However, 
further research with repeated dosing of CBD in patients would be needed to support 
or refute this possibility. Neurobiologically, that these effects were confined to low 
frequency users fits with research suggesting that high frequency cannabis users have a 
reduction in anandamide(55), potentially as a result of chronic cannabis use, which may 
mean their endocannabinoid systems are less sensitive to exogenous cannabinoids. In 
addition, a subtle pro-cognitive effect of CBD was observed on the trailmaking task, but 
only as an increase in psychomotor speed, without any impact on cognitive flexibility, 
hence this finding should be treated with caution.  
 
This study has several strengths; it used a large sample size in a four-way cross-over in a 
highly controlled laboratory setting and the use of well-validated tasks. The Volcano 
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Vaporiser method of administering cannabinoids produces similar plasma and pulmonal 
THC levels in comparison to smoked cannabis cigarettes(56) and delivers between 80% 
of the loaded THC(58). Limitations of the current study include not having plasma 
measures of THC and CBD, therefore we were not able to accurately verify our 
controlled inhalation procedure, although it has been verified in previous research(38). 
 
In summary, our study replicated previous findings of a pro-psychotic effect of THC for 
some psychotic symptoms e.g. negative symptoms, cognitive disorganisation and 
perceptual distortions and extended these to include a similar effect of a combination 
when given in a 2:1 ratio (CBD: THC). Cognitive impairments were evident following 
THC and the combination but no cognitive impairments were observed following CBD 
alone. CBD was able reduce sub-clinical psychotic-like symptoms in low frequency 
cannabis users, but not in those using the drug more heavily. This highlights a potentially 
important area of further research, given the therepeutic potential of CBD for psychosis 
and the high incidence of cannabis use disorders in this population.  
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Table 1: Means (SD) for demographic, mental health and drug use variables for light and 
heavy cannabis users  
 
Light Heavy 
 
Low 
Schizotypy 
High 
Schizotypy 
Low 
Schizotypy 
High 
Schizotypy 
Age 21.00 (2.13) 22.90 (2.02) 21.42 (1.62) 21.5 (1.38) 
Gender Ratio (m:f) 9:3 7:5 11:1 7:5 
Education (years) 15.75 (1.22) 15.79 (1.30) 15.04 (1.77) 14.5 (2.31) 
BDI-11 3.25 (3.91) 7.67 (7.10) 3.00 (1.70) 15.75 (12.96) 
SPQ 9.25 (12.66) 22.83 (11.84) 10.58 (7.07) 22.8 (17.07) 
STAI 35.67 (10.29) 41.67 (8.19) 33.00 (6.63) 42.58 (10.25) 
Spot The Word Task 51.17 (5.13) 49.75 (4.37) 51.42 (4.89) 48.75 (4.94) 
Cannabis (N) 12 12 12 12 
Cannabis used (years) 5.88 (3.48) 6.91 (3.00) 5.92 (2.15) 5.33 (2.39) 
Cannabis use 
(days/month) 11.92 (6.84) 11.71 (10.24) 24.38 (9.06) 26.00 (5.64) 
Days since last use 2.50 (1.38) 13.83 (33.64) 4.66 (8.15) 1.92 (0.79) 
Time to smoke 3.5g (days) 11.50 (15.83) 20.54 (16.13) 7.52 (8.84) 3.92 (2.75) 
Alcohol (N) 12 12 12 12 
Alcohol used (years) 6.04 (2.18) 6.71 (2.66) 6.5 (2.19) 5.25 ( 7.85) 
Alcohol (days/month) 11.54 (5.66) 8.04 (4.87) 10.00 (7.67) 11.12 (7.43) 
Tobacco (N) 6 9 10 9 
Tobacco used (years)  4.57 (1.90) 5.22 (2.54) 5.5 (2.37) 5.83 (3.02) 
Tobacco (days/month) 20.00 (11.40) 22.45 (12.16) 23.8 (10.89) 27.56 (7.33) 
Tobacco cigarettes/day 6.66 (3.77) 6.39 (3.12) 8.55 (5.31) 9.22 (4.47) 
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Table 2: Estimated marginal means and standard error (SE) for the Schizotypy by 
Subscale interaction on the Psychotomimetic States Inventory (PSI), collapsed acrosss 
drug conditions.  
 High Schizotypy Low Schizotypy 
 M SE M SE 
Delusionary thinking 1.42 0.28 0.59 0.28 
Perceptual Distortion 1.48 0.30 1.10 0.30 
Cognitive Disorganisation 7.81 0.73 4.03 0.73 
Anhedonia 6.37 0.50 3.48 0.50 
Mania 4.77 0.40 3.05 0.40 
Paranoia  1.85 0.39 0.27 0.39 
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Figure 1: Effects of THC and CBD alone and in combination, along with placebo, across 
the whole sample on subscales of psychotomimetic symptoms (PSI). THC and 
THC+CBD increased perceptual distortions (B) and cognitive disorganisation (C) but 
not other subscales. THC=T (Black shading), THC+CBD= T (grey shading), CBD= C, 
Placebo = P 
 
 
 
Figure 2: Analysis of effects of THC, CBD, the combination and placebo in low 
frequency (light) and high frequency (heavy) cannabis users on total psychotomimetic 
symptom scores 
 
 
Figure 3: Effects of THC, CBD, the combination and placebo on positive and negative 
symptoms on the Brief Psychiatric Rating Scale 
 
 
Figure 4: Effects of THC, CBD, the combination and placebo on episodic memory on 
the prose recall task 
 
 
 
Figure 5: Effects of THC, CBD, the combination and placebo on working memory in the 
N back task, for (A) d’ an index of discriminability, and (B) reaction time on the task 
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